265 related articles for article (PubMed ID: 22649143)
1. Sarcopenia during androgen-deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Sieber PR; Tammela TL; Ke C; Leder BZ; Goessl C
J Clin Oncol; 2012 Sep; 30(26):3271-6. PubMed ID: 22649143
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
3. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
5. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
[TBL] [Abstract][Full Text] [Related]
6. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
[TBL] [Abstract][Full Text] [Related]
7. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
8. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
[TBL] [Abstract][Full Text] [Related]
9. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
10. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
11. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
12. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.
van Londen GJ; Levy ME; Perera S; Nelson JB; Greenspan SL
Crit Rev Oncol Hematol; 2008 Nov; 68(2):172-7. PubMed ID: 18706829
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.
Dalla Volta A; Palumbo C; Zamboni S; Mazziotti G; Triggiani L; Zamparini M; Maffezzoni F; Rinaudo L; Bergamini M; Di Meo N; Caramella I; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Berruti A
J Endocrinol Invest; 2024 Feb; 47(2):335-343. PubMed ID: 37458931
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
Lee CE; Leslie WD; Lau YK
BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
Padhi D; Higano CS; Shore ND; Sieber P; Rasmussen E; Smith MR
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1967-75. PubMed ID: 24971661
[TBL] [Abstract][Full Text] [Related]
16. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy.
Uth J; Hornstrup T; Schmidt JF; Christensen JF; Frandsen C; Christensen KB; Helge EW; Brasso K; Rørth M; Midtgaard J; Krustrup P
Scand J Med Sci Sports; 2014 Aug; 24 Suppl 1():105-12. PubMed ID: 24944134
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
[TBL] [Abstract][Full Text] [Related]
18. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
20. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]